CTLA4 and neoplasm: As NeoAg vaccines have demonstrated favorable safety profiles6,7, combining NeoAg vaccines with single agent ICT may yield robust anti-tumor immunity with less toxicity than anti-CTLA-4 and anti-PD-1 combination ICT69–72.